Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2-breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial

Prat, A.Falato, C.Pare Brunet, L.Martinez Saez, O.Cejalvo Andujar, J. M.Margeli Vila, M.Tolosa, P.Salvador Bofill, F. J.Cruz Jurado, J.Gonzalez-Farre, B.Sanfeliu Torres, E.Ciruelos, E. M.Espinosa-Bravo, M.Izarzugaza Peron, Y.Pernas Simon, S.Esker, S.Fan, P-D.Ferrero Cafiero, J. M.Pascual, T.Oliveira, M.2023-05-032023-05-032022-05-050923-7534http://hdl.handle.net/10668/21909enPatritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2-breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trialconference outputopen access10.1016/j.annonc.2022.03.2791569-8041http://www.annalsofoncology.org/article/S0923753422007578/pdf792494100092